




The relative strengths and weaknesses of Cytomx Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytomx Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 3.7% points. The greatest weakness of Cytomx Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 133% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 94% points below the market average of 238%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	303,335	Assets	341,282
Cost of Goods Sold	0	Liabilities	290,169
Intangible Assets	949	Expenses	167,957
Liabilities, Current	85,590	Revenues	57,489
Liabilities, Non-Current	204,579	Stockholders Equity	51,113
Other Assets	29,626	Net Income	-102,238
Other Compr. Net Income	150	Comprehensive Net Income	-102,163
Other Expenses	-427	BaseVar	432,638
Other Liabilities	0	ECR before LimitedLiability	2.9%
Other Net Income	8,230	Economic Capital Ratio	144%
Other Revenues	57,489		
Property and Equipment	7,372		
Research and Development	131,619		
Selling, General and Administrative Expense	36,765		